<DOC>
	<DOCNO>NCT00327093</DOCNO>
	<brief_summary>Primary Objective : This trial elaborate model rapidly predict ( day 21 ) response monoclonal antibody anti-EGFR anti-VEGF ( cetuximab bevacizumab ) base biological marker and/or functional imaging . The response treatment evaluate conventional method 2 month ( Response Evaluation Criteria Solid Tumors [ RECIST ] criterion ) . Secondary Objectives : 1 . This trial also analyze correlation magnitude response treatment 2 month ( stabilization objective response , RECIST criterion ) response observe 6 month treatment . 2 . The organisational objective develop tumour bank metastatic colorectal cancer . Population : The population include 252 male female patient metastatic colorectal cancer justify use cetuximab bevacizumab , heart disease . Techniques : Computed tomography ( CT scan ) , functional imaging ( ultrasound SonoVue ) ; molecular imaging ( positron emission tomography [ PET ] fluorodeoxyglucose F18 [ 18-FDG ] ) ; biology pathology microbiopsy liver metastasis use . Outcome Criteria : The primary outcome response treatment monoclonal antibody accord RECIST criterion two month . Studied Factors : Radiology : 1 . CT scan : RECIST criterion ( gold standard ) ; 2 . Ultrasound SonoVue injection : 1 representative target ( delay contrast appearance , peak rising , curve increase decrease signal , area curve , time average transit ) . Nuclear Medicine : PET scan 18-FDG ( standard uptake value [ SUV ] ) Molecular Characterization Tumors : p53 status ; microsatellite instability ( MSI ) status ; expression oncogene ; EGFR status ; VEGF status ; determination FcgammaRIIIA polymorphism Statistics : 1 . Descriptive analysis ; 2 . Analysis appropriate threshold measure : response treatment ultrasound SonoVue PET scan ; correlation response predict ultrasound SonoVue PET ; conventional morphological CT 2 month 3 . Analysis prognostic factor : 1 . Evaluation role prognostic factor ( pathology image ) response treatment ; 2 . Multivariate analysis prognostic factor ; 3 . Analysis prognostic power early response 2 month response observe 6 month treatment .</brief_summary>
	<brief_title>Elaboration Model Predicting Efficacy Monoclonal Antibodies ( Cetuximab Bevacizumab ) Patients With Colorectal Cancer Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients &gt; = 18 year old Patients colon rectal carcinoma histologically proven Patients metastasis ( synchronous metachronous ) Patients associate extrahepatic disease ( asymptomatic primary tumor extrahepatic metastasis ) Performance status ( World Health Organization [ WHO ] ) = 0 , 1 , 2 Life expectancy &gt; = 3 month Patients normal haematological , kidney , liver parameter ( PNN &gt; 1.5 x 10^9/L , platelet &gt; 100 10^9/L , total bilirubin &lt; = 1.25 x upper limit normal ( ULN ) , ASAT/ALAT &lt; = 5 x ULN , creatinaemia &lt; = 135 Âµmol/L ( 1.5 mg/dL ) No cardiac coronary insufficiency untreated At least 4 week surgery study begin Patients biopsy hepatic lesion identify ultrasound . Informed consent sign . Patients symptomatic tumor ( colon rectal ) Patients others tumor cure Patients treat 5fluorouracil ( 5FU ) and/or irinotecan special medical condition serious disease . Patients participate another clinical trial since less 30 day Pregnancy breastfeed woman Patients treat active infection serious disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Colorectal cancer ,</keyword>
	<keyword>immunohistochemistry ,</keyword>
	<keyword>monoclonal antibody ,</keyword>
	<keyword>predictive model ,</keyword>
	<keyword>antiangiogenic agent ,</keyword>
	<keyword>medical imaging</keyword>
	<keyword>Colorectal cancer liver metastasis</keyword>
</DOC>